Study of NM8074 in Adult C3 Glomerulopathy Patients

NCT05647811 | Not Yet Recruiting Phase 1 FDA Drug

• 1 other identifier: NM8074-C3G-101
• Study Type: interventional
• Target: 18
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.

Conditions

C3 Glomerulopathy

Outcome Measures

Primary Outcomes (5)

• Monitoring for incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Change from Baseline or Percent Change from Baseline in Urine Protein to Creatine Concentration Ratio (UPCR)

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Change from Baseline or Percent Change from Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR)

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Ratio to Baseline of UPCR and UACR

  Derived from 24h urine collection

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Change from Baseline or Percent Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

Secondary Outcomes (12)

• Percent Change from Baseline in Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Classical Pathway (CP) of Complement Activity as Measured by Percent Change in Levels of Membrane Attack Complex (MAC)

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Percent Change from Baseline in Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Classical Pathway (CP) of Complement Activity as Measured by Percent Change in Levels of Complement Component C3b

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Change from Baseline or Percent Change from Baseline in Serum C3 Levels

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Change from Baseline or Percent Change from Baseline in Glomerular Inflammation

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Change from Baseline or Percent Change from Baseline in Quality of Life (QoL) Assessed via the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale, Version 4.

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

Other Outcomes (2)

• Change from Baseline or Percent Change from Baseline in Levels of Complement Component C3b via Classical Pathway (CP) of Complement Activity.

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

• Change from Baseline or Percent Change from Baseline in Levels of Membrane Attack Complex (MAC) via Classical Pathway (CP) of Complement Activity.

  Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

Study Arms (3)

Cohort 1

EXPERIMENTAL

6 subjects will receive NM8074 at 5 mg/kg weekly.

Drug: NM8074

Cohort 2

EXPERIMENTAL

6 subjects will receive NM8074 at 10 mg/kg every 2 weeks.

Drug: NM8074

Cohort 3

EXPERIMENTAL

6 subjects will receive NM8074 at 20 mg/kg every 2 weeks.

Drug: NM8074

Interventions

NM8074 DRUG

NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.

Cohort 1; Cohort 2; Cohort 3

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients ≥ 18 and ≤ 65 years at the time of consent
• Diagnosis of C3 Glomerulopathy as confirmed by C3 nephropathy in biopsy within 12 months prior to enrollment
• Reduced serum C3 levels (defined as less than 0.85 x lower limit of the central laboratory normal range) at Screening
• Patients with confirmed proteinuria
• Willing and able to understand and complete informed consent procedures, including signing and dating the informed consent form (ICF), and comply with the study visit schedule
• Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must have a negative pregnancy test at screening and must agree to use highly effective methods of contraception during dosing and for 1 week after stopping of investigational drug
• Males must agree to use contraceptives and refrain from donating sperm for the duration of the study
• Patients must have documentation of previous vaccination or be willing to be vaccinated prior to dosing with NM8074. All patients will be vaccinated against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae according to the most current Advisory Committee on Immunization Practices (ACIP) recommendations.
• Estimated glomerular filtration (eGFR) rate of ≤ 60 ml/min but ≥ 20 ml/min

You may not qualify if:

• Use of other investigational drugs at the time of enrollment
• Patients with other renal diseases that would interfere with interpretation of the study
• Estimated glomerular filtration rate of ≤ 20 mL/min/1.73m2 based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) at Screening
• Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 times the upper limit of normal (xULN)
• Has a known history of meningococcal disease or N. meningitidis
• Currently active systemic infection or suspicion of active bacterial, viral, or fungal infection that requires antibiotic, antifungal, antiparasitic, or antiviral mediations
• Temperature \> 38°C for more than two weeks prior to screening
• History of renal organ transplantation
• Pregnant, planning to become pregnant, or nursing female subjects
• C3G patients currently under complement blocker treatments
• Participation in any experimental small molecule or non-antibody therapy within 60 days prior to dosing on Day 1 (participation in observational studies and/or registry studies is permitted)

Sponsors & Collaborators

• NovelMed Therapeutics: lead

Central Study Contacts

Rekha Bansal

CONTACT

216-440-2696; clinicalsae@novelmed.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: The study will enroll a planned number of 18 patients as subjects for the trial with the potential for more enrollment. Each cohort will consist of 6 subjects in a total of three cohorts at doses of 5, 10, or 20 mg/kg NM8074. No more than two to three subjects will be dosed in a single day. Safety data will be assessed and reviewed by the Sponsor and Study Investigators for dosed subjects prior to dose escalation or dosing of the rest of the study subjects within the Cohort. Dose escalation will occur only after four (4) subjects have been dosed and safety data has been evaluated.

Study Record Dates

• First Submitted: November 18, 2022
• First Posted: December 13, 2022
• Study Start (Estimated): May 1, 2027
• Primary Completion (Estimated): August 1, 2029
• Study Completion (Estimated): July 1, 2030
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share